Animal Drug Compounding Market (2026 - 2033) Size, Share & Trends Analysis Report By Product (Anti-infective Agents, CNS Agents), By Animal Type (Companion Animal, Livestock Animals), By Route of Administration, By Dosage Form, By Region, And Segment Forecasts

Animal Drug Compounding Market Summary

The global animal drug compounding market size was estimated at USD 1.68 billion in 2025 and is projected to reach USD 3.25 billion by 2033, growing at a CAGR of 8.52% from 2026 to 2033. The market is advancing due to increasing demand for personalized veterinary therapies, shortages and discontinuation of commercial veterinary drugs and rising pet ownership and veterinary spending.

Rising complexity in veterinary care is driving demand for personalized drug formulations customized to diverse animal needs. The standardized medications often fail to provide precise dosing, suitable delivery routes, or acceptable palatability. Besides this, compounding enables veterinarians to adjust strength, formulation, excipients, and flavor, improving compliance and therapeutic outcomes. In addition, personalized therapies are particularly important for small mammals, geriatric animals, and chronic cases requiring long-term treatment. In addition, compounded drugs can be prepared as flavored suspensions, micro-dosed capsules, or transdermal gels to match species-specific requirements.

In addition, ongoing supply disruptions and discontinuation of veterinary drugs are increasing reliance on compounding to maintain continuity of care. The market withdrawals due to limited demand, manufacturing challenges, or regulatory changes often leave treatment gaps, particularly for niche species and specialized conditions. Besides this, veterinary compounding enables pharmacists to recreate discontinued medications or prepare therapeutic alternatives, ensuring uninterrupted access to essential therapies. This is especially critical for chronic, geriatric, and specialty treatments with limited commercial substitutes. In addition, growing supply chain volatility, raw material shortages, and shifting manufacturing priorities have made compounding an indispensable support system, particularly for rural veterinary practices and specialty clinics facing constrained drug availability.

Furthermore, rising global pet ownership, particularly among urban and middle-income households, is driving increased demand for veterinary care and personalized treatments. Besides this, pets are regarded as family members, encouraging higher spending on diagnostics, preventive care, and specialized therapies. Thus, compounded medications provide flexible, veterinarian-directed solutions when standard commercial products are unsuitable, especially for chronic diseases, pain management, and geriatric conditions. In addition, veterinary spending continues to grow across North America, Western Europe, and Asia Pacific, supported by rising disposable incomes and expanding pet insurance coverage. In the U.S., widespread pet ownership across multiple species further strengthens demand for customized, species-specific compounded formulations.

Tariff Impact on Animal Drug Compounding Sector

Market Concentration & Characteristics

The animal drug compounding sector remains fragmented, with competition driven by specialized pharmacy operators and regional providers. Prominent participants include Wedgewood Pharmacy, Vimian, Akina Animal Health, Triangle Compounding, Davis Islands Pharmacy, Custom Med Compounding Pharmacy, Central Compounding Center South, and Wellness Pharmacy. Market activity reflects a strong emphasis on inorganic growth strategies, particularly expansions, acquisitions, and partnerships, to broaden service capabilities and therapeutic coverage. Companies continue to strengthen technology platforms, scale production capacity, and extend offerings across companion and large animal segments to reinforce market positioning and capture evolving veterinary demand.

The animal drug compounding market demonstrates moderate to high innovation, driven by demand for customized dosage forms, flavored formulations, transdermal preparations, and species-specific strengths. Advancements in sterile compounding techniques, quality assurance technologies, and digital prescription management systems enhance safety and precision. For instance, in June 2025, Wedgewood Pharmacy launched its new compounded oral antiviral formulation, GS‑441524, expanding its treatment options for feline infectious peritonitis (FIP). With this addition, veterinarians can now access both GS‑441524 and Molnupiravir two of the most in-demand compounded antivirals for FIP through a single, trusted source, supported by pharmacist expertise and FDA-registered ingredient sourcing.

M&A activity in the animal drug compounding market is steadily increasing as larger pharmacy networks and veterinary service providers acquire regional compounding pharmacies to expand geographic reach and service capabilities. For instance, in December 2024, Grey Wolf Animal Health Corp, a diversified healthcare company headquartered in Toronto, Canada, has completed the acquisition of the Compounding Pharmacy of Manitoba (CPM) for USD 22.5 million, including related real estate assets. The transaction was executed under the terms of a Share Purchase Agreement.

Regulations significantly influence the market, particularly in regions such as the U.S., where oversight by the FDA and state pharmacy boards governs compounding practices. Compliance with sterile preparation standards, documentation requirements, and quality controls increases operational costs but ensures patient safety.

Commercially manufactured veterinary drugs represent the primary substitute for compounded medications. When approved, standardized products are available in suitable strengths and dosage forms, veterinarians may prefer them due to established safety and efficacy data. However, shortages, discontinuations, or lack of species-specific formulations often limit substitution, sustaining demand for customized compounded alternatives.

End user concentration is moderately high, with demand primarily driven by veterinary clinics, specialty animal hospitals, and large veterinary hospital networks. Companion animal practices account for the majority of prescriptions, particularly for chronic and geriatric conditions.

Route of Administration Insights

On the basis of route of administration, oral segment dominated the market with largest revenue share of 66.30% in 2025. Oral drug administration is the most widely used route in veterinary compounding due to its convenience, non-invasive nature, and ease of at-home use. Some of the formulations such as liquids, powders, pastes, suspensions, capsules, and flavored chewables improve compliance in both companion and livestock animals. Besides this, proper preparation is essential to ensure accurate absorption and minimize side effects. For instance, in 2024, Stokes Pharmacy partnered with Bova Group to introduce GS-441524 oral suspensions and tablets for feline infectious peritonitis in the U.S. FDA GFI #256 further supports oral compounding when no approved alternatives exist, including substances such as amantadine, clomipramine, and acetyl d-glucosamine.

The topical route plays a vital role in treating skin, ear, eye, and wound conditions in animals by delivering localized therapy through creams, ointments, gels, and sprays while minimizing systemic effects. Compounding enables customized formulations, including adjusted concentrations, combined actives, and irritant-free bases tailored to individual needs. Besides this, drug absorption may vary due to skin thickness, fur density, and grooming behavior. Transdermal gels, commonly used for methimazole, zonisamide, buspirone, and cyproheptadine, provide an alternative when oral dosing is challenging. For instance, in 2024, Fagron introduced advanced compounded creams featuring enhanced absorption technologies, supporting improved therapeutic consistency and treatment adherence.

Animal Insights

On the basis of animal, companion animals segment dominated with largest revenue share in 2025, this segment comprises of dogs, cats and other companion animals. The segment is driven by rising pet ownership, increased veterinary spending, and the demand for personalized medications. Pet owners are increasingly seeking customized therapies for their animals, especially when commercial drugs are not suitable due to species-specific needs, dosage limitations, or ingredient intolerances. This is particularly relevant for cats, dogs, and exotic pets that may have difficulty with standard tablet or capsule formulations. Compounding allows for the preparation of flavored suspensions, chewable, transdermal gels, and customized capsules that improve medication adherence and animal comfort. Besides this, behavioral issues, chronic pain, endocrine disorders, and age-related conditions in companion animals often require long-term medication making consistent, palatable, and precisely dosed formulations essential.

The livestock animal segment represents the second fastest growing segment over the forecast period and is a key focus area in the animal drug compounding market, given the complexity of therapeutic needs in food-producing species. Compounding for livestock animals such as cattle, swine, sheep, and goats is often driven by the unavailability of approved drugs tailored to specific disease profiles, regional farming practices, or herd-level health demands. In addition, common conditions requiring compounded solutions range from reproductive disorders and mastitis to parasitic infections and metabolic imbalances, which may necessitate customized dosing strengths, delivery routes, or active ingredients not present in commercially approved formulations.

Product Insights

On the basis of product, CNS agents segment held the largest revenue share in 2025, owing to supporting treatment of seizures, anxiety, neuropathic pain, and behavioral disorders in companion animals. Commonly compounded agents include gabapentin, phenobarbital, levetiracetam, diazepam, amitriptyline, fluoxetine, and clomipramine, prepared as flavored suspensions, capsules, or transdermal gels when commercial options are unsuitable. For instance, in July 2025, FDA added gabapentin to its bulk drug substances list for office stock compounding in non-food animals, improving treatment access. In addition, a 2024 study further confirmed the pharmacokinetic consistency and safety of compounded oral gabapentin in cats, reinforcing its clinical reliability and regulatory acceptance.

The hormones and substitutes segment is expected to be the fastest growing segment in the market, as this segment plays a vital role in addressing endocrine and reproductive disorders across both companion and livestock animals. Commonly compounded therapies include levothyroxine for hypothyroidism, estrogen or progesterone for reproductive regulation, and adrenal support solutions. These formulations are often modified through customized dosing, suspensions, or flavoring adjustments not typically available through commercially manufactured drugs.

Dosage Form Insights

On the basis of dosage form, suspensions dominated the market in 2025, as they are widely used in veterinary compounding to deliver insoluble or poorly soluble drugs in a liquid form with dispersed fine particles. They enable accurate dose adjustments and easier administration, particularly for young, elderly, or debilitated animals that struggle with tablets or capsules. Besides this, in dogs and cats, compounded suspensions are often flavored to enhance palatability and improve compliance. In addition, veterinary pharmacists customize drug concentration, excipients, and viscosity to meet species-specific requirements. Common examples include metronidazole for protozoal infections, omeprazole for gastrointestinal disorders, and amlodipine for feline hypertension, ensuring stability, acceptability, and therapeutic effectiveness.

The other dosage form is the fastest growing segment over the forecast period. It includes gels, ointments, and creams that significantly contribute to growth in the animal drug compounding market by enabling localized and transdermal delivery, particularly for animals that resist oral medications. These semi-solid formulations allow targeted treatment of dermatological conditions, wound infections, inflammation, and pain while reducing systemic side effects. Besides this, compounded antibiotic and antifungal creams are commonly used for skin infections, while anti-inflammatory gels help manage arthritis in companion animals. in addition, transdermal gels improve treatment adherence, such as methimazole for feline hyperthyroidism and fluoxetine for behavioral conditions

Regional Insights

North America dominated the market with largest revenue share of 37.26% in 2025.The presence of established compounding pharmacies such as Summit Veterinary Pharmacy Ltd., PETSCRIPTIONS.CA, and Victoria Compounding Pharmacy has significantly supported market growth in Canada. These pharmacies enhance access to customized veterinary medications tailored to specific animal needs. Strategic initiatives further strengthen the market landscape. For instance, in December 2024, Grey Wolf Animal Health Corp., based in Toronto, acquired the Compounding Pharmacy of Manitoba, expanding its pharmacy business unit and production capacity. Combined with its earlier acquisition of Trutina, this move broadens Grey Wolf’s customer base and improves access to specialized compounded drugs, reinforcing regional growth in veterinary compounding services.

U.S. Animal Drug Compounding Market Trends

The animal drug compounding market in the U.S. accounted for the highest market share in the North America market, owing to rising chronic conditions in companion animals, including arthritis, CNS-related behavioral disorders, and dermatological diseases, that are increasing demand for customized anti-inflammatory, CNS, and topical compounded therapies. In addition, pet humanization and higher veterinary spending, supported by pet insurance expansion, are further driving adoption of specialized treatments. Besides this, U.S. competitive landscape is led by veterinary-focused compounders such as Wedgewood Pharmacy, which serves over 70,000 veterinarians through integrated clinic and home delivery platforms. Some of its recent innovations include feline-friendly molnupiravir and GS-441524 formulations for FIP treatment in late 2024 for expanding therapeutic options.

Canada animal drug compounding market is expected to grow at a significant CAGR during the forecast periodpropelled by specialized pharmacies such as MEDS Canadian, Aurora Compounding, and Victoria Compounding, offering customized formulations including flavored suspensions and topical gels. In addition, operations follow provincial licensure rules under valid veterinarian-client-patient relationships aligned with CVMA standards. For instance, in December 2024, Grey Wolf Animal Health Corp acquired the Compounding Pharmacy of Manitoba for USD 22.5 million, expanding national distribution through its 25,000 sq ft facility. Furthermore, cross-border collaboration with U.S. firms supports regulatory-compliant development.

Europe Animal Drug Compounding Market Trends

The animal drug compounding market in Europe was identified as a lucrative region, driven by several factors, including the increasing demand for personalized veterinary care and the need for tailored medications that address specific health conditions in animals. With a limited number of FDA or EMA-approved veterinary drugs for certain species or medical conditions, compounded drugs play a crucial role in providing effective alternatives. In addition, regulations within the European Union, such as the Veterinary Medicinal Products Regulation, support the safe use of compounded medications, ensuring that veterinary pharmacies maintain high standards of quality and safety, which helps build trust in compounded animal drugs. This regulatory environment, along with advancements in compounding technology, contributes to the expansion of the market.

The animal drug compounding market in UK is expected to grow significantly over the forecast period. The market is characterized by strategic partnerships and the introduction of innovative, life-saving treatments. The increasing pet humanization and demand for personalized therapies; rising awareness among veterinarians about off-label human drugs such as cisapride or potassium bromide (often only available via compounding) to treat conditions without veterinary-approved alternatives; and regulatory pressure to comply with antimicrobial stewardship while allowing access to medically necessary compounds is driving market growth. Moreover, the competitive landscape in the UK involves specialized veterinary compounding pharmacies offering oral liquids, topical gels, and custom-dose capsules. Several UK pharmacies align with EU standards post‑Brexit and serve veterinary clinics via professional networks

The Germany animal drug compounding market held largest share in 2025 in Europe. The country’s growth is influenced by advanced veterinary infrastructure and regulations that foster strong demand for compounded medications customized to both companion and livestock species. Oral dosage forms particularly suspensions and capsules continue to lead usage, while increasing stability and palatability needs are promoting solutions and topical forms for anti‑inflammatory and hormone therapies. In addition, regulatory oversight encourages the adoption of high‑quality compounding practices that drive innovations pioneered by global names such as Pharmaca and Wedgewood, even if those companies operate outside Germany.

Asia Pacific Animal Drug Compounding Market Trends

Asia Pacific is expected to grow at a fastest CAGR over the forecast period. The region's growth can be attributed to increasing demand for customized veterinary medications for both companion animals and livestock. The rise in pet ownership, particularly in urban regions, has contributed to a higher incidence of chronic diseases in animals, creating a significant need for compounded drugs that offer tailored treatments. In addition, the growing livestock sector in countries such as China and India has spurred demand for specialized treatments aimed at improving productivity and animal health.

The animal drug compounding market in China held the largest revenue share andis witnessing new growth opportunities due to the country's vast livestock industry and the increasing demand for personalized veterinary care in companion animals. China remains the world’s largest producer and consumer of pork, creating a significant demand for compounded medications that cater to the prevention and treatment of livestock diseases. According to a report by the World Organisation for Animal Health (WOAH) published, the China Animal Disease Control Center highlighted the significant impact of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) on the swine industry in China. In addition, rising urbanization and pet ownership are expanding the market for customized medications for companion animals, particularly for chronic conditions like arthritis and infections.

The market for animal drug compounding in India is witnessing notable growth due to the country's expanding pet care sector and large livestock population. The rise in disposable incomes and pet adoption, particularly in urban areas, is propelling the demand for personalized veterinary treatments. This shift in consumer behavior is creating a growing need for compounded medications for companion animals.

Latin America Animal Drug Compounding Market Trends

The animal drug compounding market in Latin America is driven by strong livestock sector and a rising trend in pet ownership. Latin America is home to some of the largest livestock populations in the world, particularly in Brazil, Argentina, and Mexico. The need for compounded veterinary medications in these countries is growing, driven by the demand for customized treatments to address common livestock diseases such as mastitis, foot-and-mouth disease (FMD), and respiratory infections in cattle and poultry. Simultaneously, the region is witnessing a steady rise in pet ownership, especially in urban areas. This trend is contributing to increased demand for personalized veterinary care for companion animals.

Brazil animal drug compounding marketis gaining momentum due to its strong livestock industry and rising pet ownership. As one of the world’s largest beef producers, generating 11.4 million tons in 2024 (USDA FAS), Brazil requires specialized compounded treatments for mastitis, respiratory diseases, and avian influenza. Simultaneously, with approximately 168 million pets reported by the Brazilian Pet Institute, demand for customized therapies for arthritis, skin allergies, and chronic conditions is increasing. In addition, urbanization and humanization of pets are accelerating veterinary spending.

Middle East & Africa Animal Drug Compounding Market Trends

Animal drug compounding market in MEA is anticipated to grow at a lucrative rate, due to poultry health needs and rising urban pet ownership. Some of the countries such as South Africa and Egypt face recurring poultry diseases, increasing demand for tailored veterinary treatments. Meanwhile, urbanization in the UAE and Saudi Arabia has boosted pet ownership, with the UAE reporting a 30% rise and a projected USD 2 billion pet market by 2025. In addition, regulatory reforms are also supporting expansion. For instance, in May 2025, Saudi Arabia’s SFDA introduced streamlined veterinary drug approval guidelines. Improving regulations and growing demand position the regional compounded veterinary market for sustained growth.

South Africa animal drug compounding market is growing due to the poultry and dairy sectors, which are vital to the agricultural economy. The poultry industry faces recurring threats such as highly pathogenic avian influenza (HPAI), prompting urgent vaccination and disease management efforts. These challenges highlight the need for customized veterinary treatments to protect flock health and productivity. Besides this, in the dairy sector, particularly in the Western Cape, compounded medications are widely used to manage mastitis and bovine respiratory disease, supporting milk production and herd health.

Saudi Arabia animal drug compounding market is fueled by the country’s significant investment in veterinary healthcare and its focus on ensuring the health of livestock and companion animals. As a major global player in the livestock and poultry sectors, Saudi Arabia emphasizes disease management and the prevention of outbreaks, creating a demand for customized medications tailored to the specific needs of animals in the region. In addition, the growing popularity of companion animals in urban areas has led to increased awareness among pet owners about the benefits of personalized veterinary treatments. These factors present substantial growth opportunities for compounding pharmacies in the coming years.

Key Animal Drug Compounding Company Insights

The global animal drug compounding market is several specialized compounding pharmacies that have emerged as notable contributors, each with distinct geographic and product/service strengths. The market is relatively competitive and fragmented due to multiple small and large companies. Moreover, companies are increasingly adopting various strategies, such as mergers and acquisitions, geographic expansions, and product launches, to expand their market shares. For instance, in December 2024, Grey Wolf Animal Health Corp, a diversified healthcare company headquartered in Toronto, Canada, has completed the acquisition of the Compounding Pharmacy of Manitoba (CPM) for USD 22.5 million, including related real estate assets. The transaction was executed under the terms of a Share Purchase Agreement.

Recent Developments

• In July 2025, Wedgewood Pharmacy launched its new compounded oral antiviral formulation, GS‑441524, expanding its treatment options for feline infectious peritonitis (FIP). With this addition, veterinarians can now access both GS‑441524 and Molnupiravir two of the most in-demand compounded antivirals for FIP through a single, trusted source, supported by pharmacist expertise and FDA-registered ingredient sourcing.

• In April 2025, The FDA has approved Faunamor, a new treatment for Ichthyophthirius multifiliis (Ich or white spot disease) in ornamental fish, including tropical fish, goldfish, and koi. This drug, containing methylthionine chloride, malachite green oxalate, and acriflavine chloride, is now legally available for treating Ich in home aquariums and outdoor ponds, marking it as the first FDA-approved treatment for this common parasitic infection.

• In June 2025, Veterinary Pharmaceutical Solutions (VPS), a leading provider of livestock pharmacy compounding, announced a significant milestone in its history with the completion of an expanded pharmacy facility in St. Peter, Minnesota marking a major step forward in the company’s growth and service capabilities.

• In January 2025, Veterinary Pharmaceutical Solutions launched UltrAmox, a new compounded water-soluble amoxicillin formulated specifically for swine and poultry. Developed with stability and performance in mind, UltrAmox has been shown in recent studies to be the most stable product on the market for up to 24 hours when used and stored as directed

Animal Drug Compounding Market Report Scope

Global Animal Drug Compounding Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global animal drug compounding market report based on product, animal, route of administration, dosage form, and region:

• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)

  • Oral

  • Injectable

  • Topical

  • Other Routes

• Animal Outlook (Revenue, USD Million, 2021 - 2033)

  • Companion Animals

    • Dogs

    • Cats

    • Others

  • Livestock Animals

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Anti-infective Agents

  • Anti-inflammatory Agents

  • Hormones & Substitutes

  • CNS Agents

  • Other Products

• Dosage Form Outlook (Revenue, USD Million, 2021 - 2033)

  • Suspensions

  • Solutions

  • Capsules & Tablets

  • Others

• Region Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • UAE

    • Saudi Arabia

    • Kuwait

    • Qatar

    • Oman